Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2024 15:46 ET | Source: Research and Markets

Global Metastatic Melanoma Therapeutics Market Anticipates Robust Growth with New Therapeutic Developments

Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Melanoma Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Growth and...
July 14, 2022 04:38 ET | Source: Research and Markets

Global Melanoma Treatment Market Report to 2027 - Growing Regulatory Approvals are Driving the Industry

Dublin, July 14, 2022 (GLOBE NEWSWIRE) -- The "Melanoma Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. In recent years, there has been a...
June 02, 2021 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
October 12, 2020 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
June 05, 2018 08:30 ET | Source: TESARO, Inc.

TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer

WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...